Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Elan to acquire Liposome

In a move to enter the oncology market, ELN will acquire LIPO for about $575 million in stock.

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE